SUBSCRIBE
SUBSCRIBE
News   Drug Development

Atox Bio Announces Dosing of the First Subject in Its Phase 1 Study of AB103

September 14, 2010 | 
1 min read
REHOVOT, Israel--(BUSINESS WIRE)--Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
Clinical research Phase I Asia
MORE ON THIS TOPIC
Collage art of a hand touching a cat. Modern and creative design with surreal style. Perfect for use in posters, editorial design, social media, digital art, and contemporary art projects
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern data center with AI server racks connected by glowing blue lines, representing artificial intelligence, advanced computing, and data processing.
Drug Development
If Data Is the New Oil, AI Is the Refinery
September 8, 2025
 · 
5 min read
 · 
Lori Ellis
Contemporary art collage of woman sitting in the lotus position, cloud, pillows against the background of the night sky. Concept of healthy lifestyle and sport. Good and relaxing sleep. Copy space.
Neuroscience
Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial
September 8, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Blue growth graph business chart data diagram on success financial presentation background with abstract up arrow bar symbol or finance marketing price statistic and economy market profit investment.
Neuroscience
Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill
September 8, 2025
 · 
2 min read
 · 
Heather McKenzie